YLYongjian Li

Yongjian Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yongjian Li has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Guiying Zhang

    Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China

    2 shared publications
  • Fang Tang

    Department of Pharmacy and Animal Experimental Center, The Second Xiangya Hospital, Central South University, Changsha,410011, China

    1 shared publication
  • Haiquan Wen

    Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital, Central South University, Changsha 410011, China

    1 shared publication
  • Min Tong

    Animal Experimental Center, The Second Xiangya Hospital, Central South University, Changsha,410011, China

    1 shared publication
  • Ming Zhao

    Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, The Second Xiangya Hospital, Central South University, Changsha 410011, China

    1 shared publication
  • Mingliang Chen

    Department of Dermatology, Xiangya Hospital of Central South University, Changsha, 410008, China

    1 shared publication

Latest Publications

  • Open Access

    Rutaecarpine ameliorates imiquimod-induced psoriasis-like dermatitis in mice associated with alterations in the gut microbiota

    by Yongjian Li, Zhengping Tan, Wencan Li, Zongxuan Li, Guiying Zhang

    Psoriasis is accepted as a chronic, inflammatory, immune-mediated skin disease triggered by complex environmental and genetic factors. For a long time, disease recurrence, drug rejection, and high treatment costs have remained enormous challenges and burdens to patients and clinicians. Natural products with effective immunomodulatory and anti-inflammatory activities from medicinal plants have the potential to combat psoriasis and complications. Herein, an imiquimod (IMQ)-induced psoriasis-like dermatitis model is established in mice. The model mice are treated with 1% rutaecarpine (RUT) (external use) or the oral administration of RUT at different concentrations. Furthermore, high-throughput 16S rRNA gene sequencing is applied to analyze the changes in the diversity and composition of the gut microbiota. Based on the observation of mouse dorsal skin changes, RUT can protect against inflammation to improve psoriasis-like skin damage in mice. Additionally, RUT could suppress the expression levels of proinflammatory cytokines (IL-23, IL-17A, IL-22, IL-6, and IFN-α) within skin tissue samples. Concerning gut microbiota, we find obvious variations within the composition of gut microflora between IMQ-induced psoriasis mice and RUT-treated psoriasis mice. RUT effectively mediates the recovery of gut microbiota in mice induced by IMQ application. Psoriasis is linked to the production of several inflammatory cytokines and gut microbiome alterations. This research shows that RUT might restore gut microbiota homeostasis, reduce inflammatory cytokine production, and ameliorate psoriasis symptoms. In conclusion, the gut microbiota might be a therapeutic target or biomarker for psoriasis that aids in clinical diagnosis and therapy.


  • Open Access

    Rutaecarpine inhibited imiquimod-induced psoriasis-like dermatitis via inhibiting the NF-κB and TLR7 pathways in mice

    by Yongjian Li, Guiying Zhang, Mingliang Chen, Min Tong, Ming Zhao, Fang Tang, Rong Xiao, Haiquan Wen